Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2025 07:45 ET | Source: OBI Pharma Inc.

浩鼎榮獲「台灣最具潛力 ADC 臨床候選藥物獎」

台灣台北, March 12, 2025 (GLOBE NEWSWIRE) -- 今（3/12）在新加坡舉行的「2025亞洲ADC大會」（ADC Asia Congress 2025 ）晚會宣布，台灣浩鼎生技（4174.TWO）榮獲「台灣最具潛力 ADC 臨床候選藥物獎（Most Promising ADC Clinical Candidate in...
March 12, 2025 07:45 ET | Source: OBI Pharma Inc.

浩鼎荣获「台湾最具潜力 ADC 临床候选药物奖」

台湾台北, March 12, 2025 (GLOBE NEWSWIRE) -- 今（3/12）在新加坡举行的「2025亚洲ADC大会」（ADC Asia Congress 2025）晚会宣布，台湾浩鼎生技（4174.TWO）荣获「台湾最具潜力 ADC 临床候选药物奖（Most Promising ADC Clinical Candidate in...
March 12, 2025 07:45 ET | Source: OBI Pharma Inc.

OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award

TAIPEI, Taiwan, March 12, 2025 (GLOBE NEWSWIRE) -- At the ADC Asia Congress 2025 held today (3/12) in Singapore, OBI Pharma (4174.TWO) was honored with the "Most Promising ADC Clinical Candidate in...
December 23, 2024 04:00 ET | Source: OBI Pharma Inc.

浩鼎、日本頂尖醣化學衍生技術公司 GlyTech簽署二協議

台灣台北, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎(4174.TWO)23日發布，與日本專注於聚醣生產和醣化學衍生技術的GlyTech, Inc.，簽署行銷和材料移轉兩項協議；日後將藉GlyTech之力，推廣日本生技製藥業採用浩鼎自主開發的GlycOBI® ADC (antibody-drug conjugate) 關鍵技術，以創造雙贏，雙方共享利益。 ...
December 23, 2024 04:00 ET | Source: OBI Pharma Inc.

浩鼎、日本顶尖糖化学衍生技术公司 GlyTech 签署二协议

台湾台北, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎(4174.TWO)23日发布，与日本专注于聚糖生产和糖化学衍生技术的GlyTech, Inc.，签署行销和材料移转两项协议；日后将借GlyTech之力，推广日本生技制药业采用浩鼎自主开发的GlycOBI® ADC (antibody-drug conjugate) 关键技术，以创造双赢，双方共享利益。 ...
December 23, 2024 04:00 ET | Source: OBI Pharma Inc.

OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production

OBI Pharma collaborates with GlyTech to advance GlycOBI® technologies in Japan, enhancing glycan production and enabling novel ADC therapeutic innovations.
June 12, 2024 05:55 ET | Source: OBI Pharma Inc.

浩鼎啟動OBI-992一/二期臨床試驗

OBI-992以TROP2為標靶的ADC 研究目的在評估治療多種實體腫瘤的安全性和有效性台灣台北, June 12, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎 (4174.TWO)今（12）日宣布，正式啟動OBI-992的人體一/二期臨床試驗。OBI-992係浩鼎自行研發，以TROP2為標靶所設計的抗體藥物複合體(antibody-drug conjugate,...
June 12, 2024 05:55 ET | Source: OBI Pharma Inc.

浩鼎启动OBI-992一/二期临床试验

OBI-992以TROP2为标靶的ADC 研究目的在评估治疗多种实体肿瘤的安全性和有效性台湾台北, June 12, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎 (4174.TWO)今（12）日宣布，正式启动OBI-992的人体一/二期临床试验。 OBI-992系浩鼎自行研发，以TROP2为标靶所设计的抗体药物复合体(antibody-drug...
June 12, 2024 05:55 ET | Source: OBI Pharma Inc.

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer Therapy

OBI-992 phase 1/2 study initiation
April 05, 2024 10:00 ET | Source: Medicovestor Inc

Medicovestor Selected as Finalist to Present Its First-in-Class ADC Platforms at JP Morgan Asset Management: Life Sciences Innovation Summit

Medicovestor named finalist for JP Morgan Asset Management: Life Sciences Innovation Summit, showcasing pioneering ADC platforms on May 14th – 15th, 2024.